AVI Enters Into Collaborations for the Development of Two Additional Exon-Skipping Products for Duchenne Muscular Dystrophy (DMD)

Collaborations Represent Key Inflection Point in AVI’s Progress in Developing Treatments for Broader DMD Population

BOTHELL, WA, Nov 15, 2011 (MARKETWIRE via COMTEX) –

EIN #71 0874241 | 501 (c) (3) tax exempt organization Donations to FED are deductible to the full extent of the law.